Donor t cells aim to block virus after transplant
NCT ID NCT07476014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether specially prepared immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for side effects and infection. The goal is to find a safe and effective way to protect high-risk patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 18 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Inclusion criteria for allogeneic hematopoietic stem cell transplantation shall be implemented in accordance with the regulations of the transplant center at the study site; 2. Patients undergoing allogeneic hematopoietic stem cell transplantation with any of the following high-risk factors for EBV infection: 1. EBV-DNA is positive in the recipient's or donor's serum, whole blood, PBMC or sorted cells before allogeneic hematopoietic stem cell transplantation; 2. EBV-DNA is positive in the recipient's whole blood, PBMC or sorted cells after allogeneic hematopoietic stem cell transplantation, but EBV-DNA in plasma is negative; 3. Allogeneic hematopoietic stem cell transplantation is performed due to treatment of EBV infectious diseases, including but not limited to: EBV-related lymphoma, chronic active EBV infection, EBV-related lymphoproliferative disorders, etc.; 4. There is a history of EBV infection in the past, and allogeneic hematopoietic stem cell transplantation is required due to other malignant diseases. 3. No age or gender restrictions; 4. The subject and the guardian understand and sign the informed consent form. Exclusion Criteria: 1. The exclusion criteria for allogeneic hematopoietic stem cell transplantation shall be implemented in accordance with the regulations of the transplant center at the study site; 2. Exclusion criteria before infusion of JYEST cell injection: 1. Severe kidney disease (creatinine clearance rate less than 50% of the normal reference value for the same age group); 2. Severe liver disease (TBil \> 2.0×ULN; ALT and AST \> 3.0×ULN); 3. Severe acute infection (opportunistic infection); 4. Expected survival period less than 6 weeks; 5. Malnutrition (weight ≤ 10th percentile for the same age group, or serum albumin ≤ 3.0 g/dL); 6. ECOG score \> 2.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prevention of EBV infection after allogeneic hematopoietic stem cell transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.